Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Rituxan for NMOSD (RESCUE)
NCT04256252Phase 4Completed
- Sponsor
- Tangdu Hospital
- Start
- Apr 2014
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of rituximab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Tangdu Hospital. Started Apr 2014; status: completed.
02
Drugs
rituximab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04256252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04256252.